In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|February 19, 2020
Centogene to Host Events Highlighting Rare Disease Day
Author(s)BioPharm International Editors
At the event, Centogene will also announce its plans to host the annual International Rare Disease Film Festival in Berlin in 2021.
Advertisement
Centogene, a Germany-based rare disease company focused on turning clinical, genetic, and biochemical data into medical solutions for physicians and pharmaceutical companies, announced it is highlighting Rare Disease Day on Feb. 29, 2020 with an event in Berlin, Germany. The company will also host simultaneous events in Mexico City, Mexico, and Lahore, Pakistan.
According to a Feb. 13, 2020 press release, the Berlin events will begin with a conference session featuring rare disease physicians, advocates, patients, and their families. Next, guests will be treated to musical performances from The Wave Quartet and Shake Stew before viewing entries from the DISORDER Film Festival that took place in San Francisco in November 2019.
At the event, Centogene will also announce its plans to host the annual International Rare Disease Film Festival in Berlin in 2021, according to the release.
"Art is the universal global language that can visualize emotions and reach people of all cultures," said Arndt Rolfs, founder and CEO of Centogene, in the press release. "Film in particular is ideally suited to encapsulating the complexity of the subject of rare diseases. We are excited to have incised the creative energy of high caliber artists for our film competition. This will help the topic of rare diseases gain the attention it deserves-after all, it affects over 350 million people worldwide."
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5